{"count": 29, "results": [{"_id": "37835462", "pmid": 37835462, "pmcid": "PMC10571931", "title": "Synergistic Effects of Metformin and Trastuzumab on HER2 Positive Gastroesophageal Adenocarcinoma Cells In Vitro and In Vivo", "journal": "Cancers (Basel)", "authors": ["Kim JS", "Kim MY", "Hong S"], "date": "2023-09-28T00:00:00Z", "doi": "10.3390/cancers15194768", "meta_date_publication": "2023 Sep 28", "meta_volume": "15", "meta_issue": "19", "meta_pages": "", "score": 50270.555, "text_hl": "Synergistic Effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and @CHEMICAL_Trastuzumab @CHEMICAL_MESH:D000068878 @@@Trastuzumab@@@ on @GENE_ERBB2 @GENE_2064 @@@HER2@@@ Positive @<m>DISEASE_Adenocarcinoma</m> @DISEASE_MESH:D000230 @@@Gastroesophageal Adenocarcinoma@@@ Cells In Vitro and In Vivo", "citations": {"NLM": "Kim JS, Kim MY, Hong S. Synergistic Effects of Metformin and Trastuzumab on HER2 Positive Gastroesophageal Adenocarcinoma Cells In Vitro and In Vivo Cancers (Basel). 2023 Sep 28;15(19):. PMID: 37835462", "BibTeX": "@article{37835462, title={Synergistic Effects of Metformin and Trastuzumab on HER2 Positive Gastroesophageal Adenocarcinoma Cells In Vitro and In Vivo}, author={Kim JS and Kim MY and Hong S}, journal={Cancers (Basel)}, volume={15}, number={19}}"}}, {"_id": "32998939", "pmid": 32998939, "title": "Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis.", "journal": "Cancer Prev Res (Phila)", "authors": ["Loomans-Kropp HA", "Chaloux M", "Richmond E", "Umar A"], "date": "2021-02-01T00:00:00Z", "doi": "10.1158/1940-6207.CAPR-20-0274", "meta_date_publication": "2021 Feb", "meta_volume": "14", "meta_issue": "2", "meta_pages": "195-204", "score": 50260.375, "text_hl": "Use of PPIs, NSAIDs, statins, or @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ reduced the odds of @<m>DISEASE_Adenocarcinoma</m> @DISEASE_MESH:D000230 @@@EAC@@@ (PPIs: 0.10; 95% CI, 0.09-0.12; NSAIDs: 0.62; 95% CI, 0.51-0.74; statins: 0.15; 95% CI, 0.13-0.17; @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@: 0.76; 95% CI, 0.62-0.93). ", "citations": {"NLM": "Loomans-Kropp HA, Chaloux M, Richmond E, Umar A. Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis. Cancer Prev Res (Phila). 2021 Feb;14(2):195-204. PMID: 32998939", "BibTeX": "@article{32998939, title={Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis.}, author={Loomans-Kropp HA and Chaloux M and Richmond E and Umar A}, journal={Cancer Prev Res (Phila)}, volume={14}, number={2}, pages={195-204}}"}}, {"_id": "35936716", "pmid": 35936716, "pmcid": "PMC9354051", "title": "AXL Promotes Metformin-Induced Apoptosis Through Mediation of Autophagy by Activating ROS-AMPK-ULK1 Signaling in Human Esophageal Adenocarcinoma", "journal": "Front Oncol", "authors": ["Hong J", "Maacha S", "Pidkovka N", "Bates A", "Salaria SN", "Washington MK", "Belkhiri A"], "date": "2022-07-22T00:00:00Z", "doi": "10.3389/fonc.2022.903874", "meta_date_publication": "2022", "meta_volume": "12", "meta_issue": "", "meta_pages": "903874", "score": 50253.45, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@-induced apoptosis requires autophagy in @<m>DISEASE_Adenocarcinoma</m> @DISEASE_MESH:D000230 @@@EAC@@@ cells. ", "citations": {"NLM": "Hong J, Maacha S, Pidkovka N, Bates A, Salaria SN, Washington MK, Belkhiri A. AXL Promotes Metformin-Induced Apoptosis Through Mediation of Autophagy by Activating ROS-AMPK-ULK1 Signaling in Human Esophageal Adenocarcinoma Front Oncol. 2022;12():903874. PMID: 35936716", "BibTeX": "@article{35936716, title={AXL Promotes Metformin-Induced Apoptosis Through Mediation of Autophagy by Activating ROS-AMPK-ULK1 Signaling in Human Esophageal Adenocarcinoma}, author={Hong J and Maacha S and Pidkovka N and Bates A and Salaria SN and Washington MK and Belkhiri A}, journal={Front Oncol}, volume={12}, pages={903874}}"}}, {"_id": "31815765", "pmid": 31815765, "title": "Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest.", "journal": "Anticancer Drugs", "authors": ["Yamashita T", "Kato K", "Fujihara S", "Iwama H", "Morishita A", "Yamana H", "Kobayashi K", "Kamada H", "Chiyo T", "Kobara H", "Tsutsui K", "Okano K", "Suzuki Y", "Masaki T"], "date": "2020-03-01T00:00:00Z", "doi": "10.1097/CAD.0000000000000870", "meta_date_publication": "2020 Mar", "meta_volume": "31", "meta_issue": "3", "meta_pages": "231-240", "score": 50249.395, "text_hl": "These results suggest that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ may be used clinically for the treatment of @<m>DISEASE_Adenocarcinoma</m> @DISEASE_MESH:D000230 @@@gallbladder adenocarcinoma@@@.", "citations": {"NLM": "Yamashita T, Kato K, Fujihara S, Iwama H, Morishita A, Yamana H, Kobayashi K, Kamada H, Chiyo T, Kobara H, Tsutsui K, Okano K, Suzuki Y, Masaki T. Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest. Anticancer Drugs. 2020 Mar;31(3):231-240. PMID: 31815765", "BibTeX": "@article{31815765, title={Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest.}, author={Yamashita T and Kato K and Fujihara S and Iwama H and Morishita A and Yamana H and Kobayashi K and Kamada H and Chiyo T and Kobara H and Tsutsui K and Okano K and Suzuki Y and Masaki T}, journal={Anticancer Drugs}, volume={31}, number={3}, pages={231-240}}"}}, {"_id": "31699708", "pmid": 31699708, "title": "Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model.", "journal": "Cancer Prev Res (Phila)", "authors": ["Madka V", "Kumar G", "Pathuri G", "Zhang Y", "Lightfoot S", "Asch AS", "Mohammed A", "Steele VE", "Rao CV"], "date": "2020-02-01T00:00:00Z", "doi": "10.1158/1940-6207.CAPR-19-0265", "meta_date_publication": "2020 Feb", "meta_volume": "13", "meta_issue": "2", "meta_pages": "185-194", "score": 50248.195, "text_hl": "However, the lower dose combinations of @CHEMICAL_Zoledronic_Acid @CHEMICAL_MESH:D000077211 @@@zometa@@@ or @CHEMICAL_Alendronate @CHEMICAL_MESH:D019386 @@@fosamax@@@ with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ resulted in significant inhibition of noninvasive @<m>DISEASE_Adenocarcinoma</m> @DISEASE_MESH:D000230 @@@adenocarcinoma@@@ by 48% (P < 0.006) and 64% (P < 0.0002), and @<m>DISEASE_Adenocarcinoma</m> @DISEASE_MESH:D000230 @@@invasive adenocarcinoma@@@ by 49% (P < 0.0005) and 38% (P < 0.006), respectively. ", "citations": {"NLM": "Madka V, Kumar G, Pathuri G, Zhang Y, Lightfoot S, Asch AS, Mohammed A, Steele VE, Rao CV. Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model. Cancer Prev Res (Phila). 2020 Feb;13(2):185-194. PMID: 31699708", "BibTeX": "@article{31699708, title={Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model.}, author={Madka V and Kumar G and Pathuri G and Zhang Y and Lightfoot S and Asch AS and Mohammed A and Steele VE and Rao CV}, journal={Cancer Prev Res (Phila)}, volume={13}, number={2}, pages={185-194}}"}}, {"_id": "37240387", "pmid": 37240387, "pmcid": "PMC10219450", "title": "Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect", "journal": "Int J Mol Sci", "authors": ["Corremans R", "Vervaet BA", "Dams G", "D'Haese PC", "Verhulst A"], "date": "2023-05-20T00:00:00Z", "doi": "10.3390/ijms24109043", "meta_date_publication": "2023 May 20", "meta_volume": "24", "meta_issue": "10", "meta_pages": "", "score": 50246.3, "text_hl": "All @SPECIES_10116 @@@rats@@@ in which @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ was induced developed @DISEASE_Hyperglycemia @DISEASE_MESH:D006943 @@@hyperglycemia@@@, hyperfiltration, @DISEASE_Proteinuria @DISEASE_MESH:D011507 @@@proteinuria@@@, @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@, @DISEASE_Renal_Tubular_Transport_Inborn_Errors @DISEASE_MESH:D015499 @@@renal tubular injury@@@ and interstitial @DISEASE_Fibrosis @DISEASE_MESH:D005355 @@@fibrosis@@@, confirming @DISEASE_Diabetic_Nephropathies @DISEASE_MESH:D003928 @@@DKD@@@. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and @CHEMICAL_Canagliflozin @CHEMICAL_MESH:D000068896 @@@canagliflozin@@@, alone or together, exerted similar renoprotective actions and similar reductions in @<m>DISEASE_Adenocarcinoma</m> @DISEASE_MESH:D000230 @@@tubular injury@@@ and collagen accumulation. ", "citations": {"NLM": "Corremans R, Vervaet BA, Dams G, D'Haese PC, Verhulst A. Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect Int J Mol Sci. 2023 May 20;24(10):. PMID: 37240387", "BibTeX": "@article{37240387, title={Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect}, author={Corremans R and Vervaet BA and Dams G and D'Haese PC and Verhulst A}, journal={Int J Mol Sci}, volume={24}, number={10}}"}}, {"_id": "35414608", "pmid": 35414608, "pmcid": "PMC9006817", "title": "Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway", "journal": "Lupus Sci Med", "authors": ["Chen XC", "Wu D", "Wu HL", "Li HY", "Yang C", "Su HY", "Liu ZJ", "Huang XR", "Lu X", "Huang LF", "Zhu SP", "Pan QJ", "An N", "Liu HF"], "date": "2022-04-01T00:00:00Z", "doi": "10.1136/lupus-2021-000611", "meta_date_publication": "2022 Apr", "meta_volume": "9", "meta_issue": "1", "meta_pages": "", "score": 50246.066, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ reduced immunoglobulin G and @GENE_C3 @GENE_12266 @@@complement C3@@@ deposition in glomeruli. ", "citations": {"NLM": "Chen XC, Wu D, Wu HL, Li HY, Yang C, Su HY, Liu ZJ, Huang XR, Lu X, Huang LF, Zhu SP, Pan QJ, An N, Liu HF. Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway Lupus Sci Med. 2022 Apr;9(1):. PMID: 35414608", "BibTeX": "@article{35414608, title={Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway}, author={Chen XC and Wu D and Wu HL and Li HY and Yang C and Su HY and Liu ZJ and Huang XR and Lu X and Huang LF and Zhu SP and Pan QJ and An N and Liu HF}, journal={Lupus Sci Med}, volume={9}, number={1}}"}}, {"_id": "33621192", "pmid": 33621192, "title": "Possible protective role of metformin therapy on colonic polyps in acromegaly: an exploratory cross-sectional study.", "journal": "Eur J Endocrinol", "authors": ["Albertelli M", "Nazzari E", "Dotto A", "Grasso LF", "Sciallero S", "Pirchio R", "Rebora A", "Boschetti M", "Pivonello R", "Ricci Bitti S", "Colao AAL", "Ferone D"], "date": "2021-03-01T00:00:00Z", "doi": "10.1530/EJE-20-0795", "meta_date_publication": "2021 Mar", "meta_volume": "184", "meta_issue": "3", "meta_pages": "419-425", "score": 50240.67, "text_hl": "Of the @SPECIES_9606 @@@patients@@@ with @DISEASE_Polyps @DISEASE_MESH:D011127 @@@polyps@@@ (including three @<m>DISEASE_Adenocarcinoma</m> @DISEASE_MESH:D000230 @@@adenocarcinomas@@@) only 24% were treated with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ vs 57% of @SPECIES_9606 @@@patients@@@ without @DISEASE_Polyps @DISEASE_MESH:D011127 @@@polyps@@@. ", "citations": {"NLM": "Albertelli M, Nazzari E, Dotto A, Grasso LF, Sciallero S, Pirchio R, Rebora A, Boschetti M, Pivonello R, Ricci Bitti S, Colao AAL, Ferone D. Possible protective role of metformin therapy on colonic polyps in acromegaly: an exploratory cross-sectional study. Eur J Endocrinol. 2021 Mar;184(3):419-425. PMID: 33621192", "BibTeX": "@article{33621192, title={Possible protective role of metformin therapy on colonic polyps in acromegaly: an exploratory cross-sectional study.}, author={Albertelli M and Nazzari E and Dotto A and Grasso LF and Sciallero S and Pirchio R and Rebora A and Boschetti M and Pivonello R and Ricci Bitti S and Colao AAL and Ferone D}, journal={Eur J Endocrinol}, volume={184}, number={3}, pages={419-425}}"}}, {"_id": "25340116", "pmid": 25340116, "pmcid": "PMC4205998", "title": "Histopathological study of the combination of metformin and garlic juice for the attenuation of gentamicin renal toxicity in rats", "journal": "J Renal Inj Prev", "authors": ["Baradaran A", "Rafieian-Kopaei M"], "date": "2013-03-01T00:00:00Z", "doi": "10.12861/jrip.2013.07", "meta_date_publication": "2013", "meta_volume": "2", "meta_issue": "1", "meta_pages": "15-21", "score": 50072.25, "text_hl": "Thus, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ has the potential of protecting @CHEMICAL_Gentamicins @CHEMICAL_MESH:D005839 @@@gentamicin@@@-induced @<m>DISEASE_Adenocarcinoma</m> @DISEASE_MESH:D000230 @@@tubular injury@@@. ", "citations": {"NLM": "Baradaran A, Rafieian-Kopaei M. Histopathological study of the combination of metformin and garlic juice for the attenuation of gentamicin renal toxicity in rats J Renal Inj Prev. 2013;2(1):15-21. PMID: 25340116", "BibTeX": "@article{25340116, title={Histopathological study of the combination of metformin and garlic juice for the attenuation of gentamicin renal toxicity in rats}, author={Baradaran A and Rafieian-Kopaei M}, journal={J Renal Inj Prev}, volume={2}, number={1}, pages={15-21}}"}}, {"_id": "22950385", "pmid": 22950385, "title": "Metformin use and improved response to therapy in esophageal adenocarcinoma.", "journal": "Acta Oncol", "authors": ["Skinner HD", "McCurdy MR", "Echeverria AE", "Lin SH", "Welsh JW", "O'Reilly MS", "Hofstetter WL", "Ajani JA", "Komaki R", "Cox JD", "Sandulache VC", "Myers JN", "Guerrero TM"], "date": "2013-06-01T00:00:00Z", "doi": "10.3109/0284186X.2012.718096", "meta_date_publication": "2013 Jun", "meta_volume": "52", "meta_issue": "5", "meta_pages": "1002-9", "score": 50072.145, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ use and improved response to therapy in @<m>DISEASE_Adenocarcinoma</m> @DISEASE_MESH:D000230 @@@esophageal adenocarcinoma@@@.", "citations": {"NLM": "Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013 Jun;52(5):1002-9. PMID: 22950385", "BibTeX": "@article{22950385, title={Metformin use and improved response to therapy in esophageal adenocarcinoma.}, author={Skinner HD and McCurdy MR and Echeverria AE and Lin SH and Welsh JW and O'Reilly MS and Hofstetter WL and Ajani JA and Komaki R and Cox JD and Sandulache VC and Myers JN and Guerrero TM}, journal={Acta Oncol}, volume={52}, number={5}, pages={1002-9}}"}}]}